Search results
Showing 1751 to 1800 of 3765 results for treatment
and long-term outcomes, with clear documentation of the indications for treatment. Any explanatory notes(if applicable) Current evidence...
Extracranial to intracranial bypass for intracranial atherosclerosis (IPG596)
Evidence-based recommendations on extracranial to intracranial bypass for intracranial atherosclerosis. This involves joining a blood vessel from outside the skull to one inside the skull to bypass a narrowed or partially blocked vessel.
Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]
Discontinued Reference number: GID-TAG399
In development Reference number: GID-IPG10448 Expected publication date: TBC
We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.
Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]
Discontinued Reference number: GID-TAG330
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
Serelaxin for the treatment of acute decompensated heart failure [ID673]
Discontinued Reference number: GID-TAG454
and cost effectiveness of cannabis-based medicinal products as an add-on treatment for babies, children and young people with persistent...
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)
Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.
View recommendations for IPG784Show all sections
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (HTG326)
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)
Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.
Photodynamic therapy for localised inoperable endobronchial cancer (IPG137)
Evidence-based recommendations on photodynamic therapy (PDT) for localised inoperable endobronchial cancer (non-small-cell lung cancer). This involves injecting a photosensitising agent into the body that is activated by laser light to destroy the cancerous tissue.
View recommendations for IPG137Show all sections
Sections for IPG137
Percutaneous tibial nerve stimulation for faecal incontinence (IPG395)
Evidence-based recommendations on percutaneous tibial nerve stimulation (PTNS) for faecal incontinence. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current through the needle to the nerves that control bowel function.
View recommendations for IPG395Show all sections
Sections for IPG395
Intravenous fluid therapy in children and young people in hospital (NG29)
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.
Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)
In development Reference number: GID-HTE10070 Expected publication date: TBC
Kidney conditions: CKD and renin–angiotensin system antagonists (IND130)
This indicator covers the percentage of patients on the chronic kidney disease (CKD) register who have hypertension and proteinuria and who are currently being treated with an angiotensin-receptor blocker or an angiotensin-converting enzyme inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM84
This indicator covers the contractor establishing and maintaining a register of all cancer patients excluding non-melanotic skin cancers. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM234
UroShield for preventing catheter-associated urinary tract infections (HTG620)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.
Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]
Discontinued Reference number: GID-TA11240
This indicator covers establishing and maintaining a register of patients with peripheral arterial disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM32
Selective internal radiation therapy for primary hepatocellular carcinoma (IPG460)
Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.
View recommendations for IPG460Show all sections
Sections for IPG460
Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.
View recommendations for IPG615Show all sections
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
NICE has developed a medtech innovation briefing (MIB) on Permacol for treating anal fistulae .
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
Transcranial magnetic stimulation for auditory hallucinations (IPG680)
Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.
View recommendations for IPG680Show all sections
Recommendation ID NG231/04A Question Endoscopic treatments: For adults with Barrett's oesophagus with dysplasia, what is the...
Focal therapy using cryoablation for localised prostate cancer (IPG423)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for IPG423Show all sections
Sections for IPG423
Micropressure therapy for refractory Ménière's disease (IPG426)
Evidence-based recommendations on micropressure therapy for refractory Ménière's disease. This involves inserting a grommet (small tube) through the eardrum into the middle ear and blowing air at low pressure into the inner ear.
View recommendations for IPG426Show all sections
Sections for IPG426
Workplace health: long-term sickness absence and capability to work (NG146)
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
cost effectiveness of selective laser trabeculoplasty as a first-line treatment compared with intraocular pressure-lowering eye drops in...
This indicator covers the proportion of people treated by Improving Access to Psychological Therapies (IAPT) for anxiety disorders who return to full function. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG54
Stroke and ischaemic attack: 4-hour admission to a stroke unit (IND34)
This indicator covers the proportion of people who have had or are having a stroke who are admitted to an acute stroke unit within 4 hours of arrival to hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG51
Pregnancy and neonates: newborn blood spot test communication within 6 weeks of birth (IND66)
This indicator covers the proportion of babies with a 'not suspected' result for all the conditions tested for by newborn blood spot testing who have a results letter sent to their parents directly from the child health information service (CHIS) within 6 weeks of birth. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG85
Bipolar, schizophrenia and other psychoses: annual blood pressure (IND84)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM17
This indicator covers producing a register of all patients aged 16 years and over with rheumatoid arthritis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM55
NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .
Discontinued Reference number: GID-TAG444
Evidence-based recommendations on drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants. This involves draining excess CSF from the brain, washing out the blood, and breaking down blood clots using drugs (fibrinolytics).
View recommendations for IPG412Show all sections
Sections for IPG412
Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)
Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.
This indicator covers the percentage of patients with hypothyroidism, on the register, with thyroid function tests recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM100
Extracorporeal albumin dialysis for acute liver failure (IPG316)
Evidence-based recommendations on extracorporeal albumin dialysis for acute liver failure. This involves using a dialysis machine to remove both water-soluble toxins and toxins that are attached to albumin and accumulate in liver failure.
View recommendations for IPG316Show all sections
Sections for IPG316
Intralesional photocoagulation of subcutaneous congenital vascular disorders (IPG90)
Evidence-based recommendations on intralesional photocoagulation of subcutaneous congenital vascular disorders. This involves inserting a laser fibre into the lesion to deliver the light deep within it.
View recommendations for IPG90Show all sections
Sections for IPG90
quality of life in people with type 2 diabetes compared with optimal medical treatment? Any explanatory notes(if applicable) Source...
Evidence-based recommendations on magnetic resonance therapy for knee osteoarthritis in adults. This involves placing a magnetic resonance device over the knee to stimulate cartilage to heal and relieve the symptoms of osteoarthritis.
View recommendations for IPG702Show all sections
This indicator covers the percentage of patients aged between 25 and 84 years, with type 2 diabetes, without moderate or severe frailty, not currently treated with a statin, who have had a consultation for a full formal cardiovascular disease risk assessment in the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM160
This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes